Milan, Italy – September 12, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
Milan, Italy and Montreal, Quebec – July 10, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of
Guidance reiterated
Milan, Italy – June 28, 2019 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies
ODDO SEYDLER BANK AG acts as Capital Market Partner of the Düsseldorf Stock Exchange and Designated Sponsor
Milan, Italy – June 27, 2019 – Shares of Newron Pharmaceuticals S.p.A
Milan, Italy and Morristown, NJ, USA - June 13, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, NJ, USA - May 28, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, NJ, USA - May 23, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy – April 2, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy, March 5, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Sponsoring international study to examine the burden of Rett syndrome on patients and caregivers, featured at Findacure’s Drug Repurposing for Rare Diseases Conference in the UK
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
